Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Odyssey Therapeutics, Inc.

Filed: May 7, 2026BostonCIK: 0001882782Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Odyssey Therapeutics completed a $25 million private placement with existing investor TPG LSI Rise Orazio II, L.P., purchasing 1,388,889 shares at $18.00 per share concurrent with the company's IPO. This signals strong investor confidence and provides additional capital to support post-IPO growth initiatives.

Key Takeaways

Company raised $25 million through private placement concurrent with IPO, demonstrating investor confidence in the business

Existing stockholder TPG LSI Rise Orazio II, L.P. made significant follow-on investment, indicating continued commitment to the company

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 7, 2026
Item1.01
CategoryMaterial Agreement
CIK0001882782
Accession #0001882782
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
ipo spacstock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings